If you’ve been keeping track of new trends in cosmetic care, you’ve probably heard the buzz around Jeuveau – a new way to freeze wrinkles in their tracks. In the event you haven’t, here’s what you need to know about this trending treatment and how it compares to industry giant Botox^®.

Jeuveau is a new FDA-approved neurotoxin treatment

Like existing competitors, Botox^®, Dysport, and Xeomin^®, Jeuveau is designed to reduce signs of aging by temporarily paralyzing facial muscles. To do so, the treatment uses a highly purified form of the botulinum toxin. While deadly in unrefined doses, the formula used in Jeuveau treatments is completely safe and as of February 2019, approved for use in treating severe frown lines that develop between the eyebrows. 

Jeuveau application is also much the same as other FDA-approved neurotoxin treatments. During your appointment, the treatment area is cleaned and prepared. The serum is then injected into the target area, causing underlying muscles to relax and smooth the skin above. During the first few hours following treatment, our specialist may recommend avoiding making exaggerated facial expressions in order to give the treatment enough time to work. Depending on the amount of product administered, the depth of wrinkles and overall goals, your results can last anywhere from three to six months. 

Jeuveau has shown the same, if not better clinical results than its main competitor

Jeuveau and Botox^® share many similarities than you would think. Beyond leveraging the same toxin to tackle unwanted wrinkles and creases, both treatments offer a duration of about three months. Clinical studies conducted before the product reached FDA-approval further highlighted these similarities, with researchers highlighting that thanks to their similar results, the products could be safely used interchangeably. During the trials, 70% of Jeuveau recipients responded positively with few adverse reactions. As such, some clinicians have gone farther to predict a similar if not more predictable and safe response from patients.

Jeuveau may be slightly more affordable than Botox^®

Similarities end when it comes to cost. At the initial launch of treatment, Jeuveau’s parent company Evolus made clear that the injectable would be made available at a much lower rate than main competitor Botox^®. In the months since FDA approval, analysts have indicated that the going rate for Jeuveau treatment may be as much as 30% less than the doing market rate. Considering the lowered cost and comparable results, its no wonder why so many cosmetic specialists and patients alike are looking for more details on this new product. 

 Jeuveau’s parent company is the first to enter the facial aesthetics market in over 10 years

In the world of cosmetic dermatology, we’re accustomed to new innovations in the way existing treatment techniques have been used. The introduction of new companies with a competitive product to offer like Evolus with Jeuveau is rare and exciting. It’s been nearly 20 years since Botox^® was first approved by the FDA for wrinkle treatment – 17 to be precise. In that time, only two new products have been launched in the realm of neurotoxins. Until now. 

Interested? Schedule Your Consultation 

At Desert Med Aesthetics, we pride ourselves on offering the latest and greatest treatment options to our patients. If you’re looking for a new way to refresh your appearance, be sure to ask our Indian Wells cosmetic specialist about the benefits of Jeuveau. Call 760-777-8772 or fill out our online form to get started!